KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2025)

Vir Biotechnology's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 28.31% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $4.5 billion, down 28.9%, while the annual FY2025 figure was $1.0 billion, 28.31% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.0 billion at Vir Biotechnology, down from $1.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.9 billion in Q1 2022 and bottomed at $1.0 billion in Q4 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2024), against an average of $1.8 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 154.24% in 2022 before it tumbled 32.71% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.0 billion in 2021, then soared by 43.38% to $2.8 billion in 2022, then plummeted by 31.51% to $1.9 billion in 2023, then dropped by 27.11% to $1.4 billion in 2024, then decreased by 28.31% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for VIR's Liabilities and Shareholders Equity are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.2 billion (Q2 2025).